North America Hepatitis B Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

North America Hepatitis B Market Overview

The North America Hepatitis B market reached a value of approximately USD 4.79 Billion in 2025. The market is expanding steadily, supported by approximately 640,000 to over one million U.S. adults with chronic HBV requiring lifelong antiviral therapy, accelerating regulatory progress for first-in-class functional cure candidates, and sustained universal HBV vaccination programs.

North America Hepatitis B Market Segmentation

North America Hepatitis B Market Growth Analysis and Key Influencers

North America Hepatitis B Market Dynamics

This section examines key growth drivers, including HBV disease burden, regulatory progress, technology adoption, cost factors, and ecosystem shifts, integrating interlinking keywords across the market landscape.

North America Hepatitis B Market Growth Drivers

Sustained Chronic HBV Demand and Pipeline Innovation Powering Market Expansion

The market is witnessing sustained expansion supported by approximately 640,000 to over one million U.S. adults with chronic HBV requiring lifelong antiviral therapy, alongside accelerating innovation in functional cure candidates. For instance, in May 2026, the FDA accepted bepirovirsen's NDA under Priority Review and granted Breakthrough Therapy designation, with a PDUFA target action date of October 26, 2026, positioning bepirovirsen as the first therapy to achieve clinically meaningful functional cure rates in chronic HBV. The launch of tenofovir alafenamide (Vemlidy) is on track to top USD 1 billion in sales, anchoring sustained antiviral demand.

North America Hepatitis B Market Restraints

Universal Vaccination and Generic Antiviral Pressure Slowing Market Penetration

Universal newborn hepatitis B vaccination since 1991 has reduced incident infections by approximately 99% in infants and children across the United States, narrowing the incident-infection pool. Generic entry into the antiviral segment (tenofovir disoproxil generics) and ongoing payer pressure on branded HBV therapies remain notable headwinds. Manufacturers continue to invest in pediatric extensions, functional cure pipelines, and combination therapies to maintain growth.

North America Hepatitis B Market Opportunities

Bepirovirsen Functional Cure Pathway Opening Significant Avenues for Market Growth

Growing investment in HBV functional cure research and increasing unmet clinical need in chronic hepatitis B management are creating strong momentum for next-generation antiviral innovation. For instance, in January 2026, GSK and Ionis Pharmaceuticals announced bepirovirsen successfully met the primary endpoint in both B-Well 1 and B-Well 2 Phase 3 trials, demonstrating statistically significant and clinically meaningful functional cure rates versus standard of care. If approved in October 2026, the therapy is expected to significantly reshape the chronic HBV treatment landscape over the forecast period by shifting care from long-term viral suppression toward potential functional cure strategies, thereby influencing treatment duration, prescribing patterns, and overall hepatology market economics.

North America Hepatitis B Market Trends

Rapid Point-of-Care Hepatitis B Diagnostics Strengthening Market Expansion

A key emerging trend in the market is the expansion of rapid, point-of-care diagnostic solutions aimed at improving early detection and screening accessibility. For instance, in May 2026, Health Canada authorized the first hepatitis B surface antigen rapid test in North America developed by bioLytical, enabling diagnosis within approximately 15 minutes in clinical and community-based settings. This development reflects a broader shift toward decentralized testing models, which is expected to significantly improve early diagnosis rates and enhance linkage to care for chronic HBV patients across the region over the forecast period.

North America Hepatitis B Market Share

Chronic Segment Likely to Dominate the Market Segment by Type

The chronic segment by type is likely to dominate the market, supported by its long-term disease progression and continuous treatment requirements. It occupied around 90% market share in the historical period, driven by sustained patient management needs and higher diagnosis rates compared to acute cases. The segment is likely to lead due to persistent therapy demand and structured clinical monitoring. Increasing reliance on Tenofovir vs entecavir in chronic HBV treatment strategies further reinforces long-term management dominance, strengthening chronic disease positioning within the broader hepatitis B therapy landscape.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

North America Hepatitis B Market Analysis by Region

The United States is likely to dominate the market, supported by strong healthcare infrastructure, high diagnosis rates, and advanced treatment accessibility. It held over 72% market share in the historical period, driven by consistent use of standardized treatment protocols and strong patient awareness. The country is likely to lead due to robust screening programs and therapy adoption rates. Increasing reliance on antiviral drugs further strengthens its position in the hepatitis B treatment market across North America.

Leading Players in the North America Hepatitis B Market

Key Questions Answered in the North America Hepatitis B Market Report

• What was the North America hepatitis B market value in 2025?
• What is the North America hepatitis B market forecast outlook for 2026-2035?
• What major factors aid the demand for the North America hepatitis B market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major North America hepatitis B market trends?
• Which type is expected to dominate the market segment?
• Which treatment is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Who are the key players in the North America hepatitis B market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with hepatologists, infectious disease specialists, gastroenterologists, and pharmacists across the US and Canada, focusing on treatment adoption, antiviral usage, diagnostics, and market trends.
• Secondary Research: Analysis of peer-reviewed journals, FDA and Health Canada updates, clinical trial data, pharma press releases, investor reports, and credible healthcare news covering North America hepatitis B landscape.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.